Prostate Cancer Screening

Similar documents
Prostate Cancer Screening. Dr. J. McCracken, Urologist

1. What is the prostate-specific antigen (PSA) test?

Early Prostate Cancer: Questions and Answers. Key Points

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

An Introduction to PROSTATE CANCER

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

The 4Kscore blood test for risk of aggressive prostate cancer

PSA Screening for Prostate Cancer Information for Care Providers

The 4Kscore blood test for risk of aggressive prostate cancer

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

PCA3 DETECTION TEST FOR PROSTATE CANCER DO YOU KNOW YOUR RISK OF HAVING CANCER?

Us TOO University Presents: Understanding Diagnostic Testing

Screening for Prostate Cancer

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER

Advances in Diagnostic and Molecular Testing in Prostate Cancer

Prostate Cancer Screening. A Decision Guide for African Americans

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

A New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY

Prostate Cancer 2014

Prostate Cancer Screening. A Decision Guide

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

SIGNPOSTS. Along the Pathway of Prostate Cancer. Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer

PROSTATE CANCER. Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American

The PSA Test for Prostate Cancer Screening:

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

Prostate cancer screening. It s YOUR decision!

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

Advice to patients about the PSA (prostate-specific antigen) blood test: frequently-asked questions

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

Prostate Cancer Screening

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

PATIENT GUIDE. Localized Prostate Cancer

Prostate Health Index Literature

Talking about Prostate Cancer

Thomas A. Kollmorgen, M.D. Oregon Urology Institute

Robert Bristow MD PhD FRCPC

Description of Procedure or Service. gene_based_tests_for_screening_detection_or_management_of_prostate_cancer 4/2009 8/2015 8/2016 8/2015

PSA screening: Controversies and Guidelines

A Woman s Guide to Prostate Cancer Treatment

Newly Diagnosed Prostate Cancer: Understanding Your Risk

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

SRO Tutorial: Prostate Cancer Treatment Options

Historical Basis for Concern

PSA screening in asymptomatic men the debate continues keyword: psa

Cancer Association of South Africa (CANSA)

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

The PSA Controversy: Defining It, Discussing It, and Coping With It

Biomarkers for Prostate Cancer. Eric Wallen, MD Department of Urology

PSA: Prostate Cancer Screening

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Prostate Cancer In-Depth

NCCN Prostate Cancer Early Detection Guideline

Cancer doesn t care but we do Cancer Annual Report

CONTENTS: WHAT S IN THIS BOOKLET

Advanced Prostate Cancer Treatments

Answering Your Questions on prostate cancer

7. Prostate cancer in PSA relapse

Gleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated

Prostate Cancer. Patient Information

DIAGNOSIS OF PROSTATE CANCER

Screening for Prostate Cancer

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Prostate Cancer Early Detection: Update 2010

Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer

Questions to ask my doctor: About prostate cancer

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.

Testing for Prostate Cancer

Use Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa

4/8/13. Pre-test Audience Response. Prostate Cancer Screening and Treatment of Prostate Cancer: The 2013 Perspective

Treating Localized Prostate Cancer A Review of the Research for Adults

MEDICAL POLICY SUBJECT: PROSTATE CANCER SCREENING, DETECTION AND MONITORING

Medical Tests for Prostate Problems

PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test

Official reprint from UpToDate UpToDate

Screening for Prostate Cancer

Prostate Cancer & Its Treatment

Prostate Cancer. What is prostate cancer?

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

THINGS TO BE AWARE OF ABOUT PROSTATE AND LUNG CANCER. Lawrence Lackey Jr., M.D. Internal Medicine 6001 W. Outer Dr. Ste 114

Understanding the PSA test. A guide for men concerned about prostate cancer

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all.

Treating Prostate Cancer

How prostate cancer is diagnosed

UKNSC Screening for Prostate Cancer Review 2015 Update

Prostate Cancer Screening in Taiwan: a must

How is Prostate Cancer Diagnosed?

Prostate Cancer in Older Men

Technologies To Detect Prostate Cancer

Prostate Cancer Action Plan: Choosing the treatment that s right for you

Understanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives.

Questions to Ask My Doctor About Prostate Cancer

Does Radiation Treatment of Prostate Cancer Increase Risk for Rectal Cancer? The Perfect Storm

Transcription:

Prostate Cancer Screening PSA and Beyond The Skinny PSA types PSA facts New tests Guidelines 1

Total PSA Produced primarily by the human prostatic epithelium PSA is normally secreted in high concentrations into seminal fluid Functions in the liquefaction of the seminal coagulum It is organ-specific but not disease-specific Can be detected in patients with normal prostate and benign prostatic hyperplasia (BPH) Disruption of basement membrane integrity prostatic infarction prostatitis ejaculation 15% 48hrs digital rectal manipulation (DRE) 0.26 to 0.4 ng/ml 24 hours prostatic instrumentation Up to 50x, may take months 2

Proof of effect in 1991 PSA + DRE vs PSA = +27% PSA + DRE vs DRE = +34% - Catalona et al Role in Screening Major cancer organizations = no universal agreement on the relationship between early detection and survival Most urologist believe the problem is not overdetection but overtreatment Shared decision Individualized screening prostaterisk.ca No screening = aggressive tumors present advanced 3

PROSTATE RISK CALCULATOR Age: range (30-90) IPSS(Urinary voiding Symptom score): range (0-35) PSA: range (0.1-50) FTPSA (Free:total PSA ratio): range(0.01 -.99) Ethnic Background: Asian Caucasian African Desent Other Family history of prostate cancer: Abnormal DRE(by Doctor): Yes No Age:39 IPSS:13 PSA:2.6 FTPSA (Free:total PSA ratio):0.14 Ethnic Background:Caucasian Family history of prostate cancer:yes Abnormal DRE(by Doctor):No 4

Predicting Outcomes If younger than 60 0.7-0.9 ng/ml > age corrected N Lifetime increased risk of prostate cancer < 1.0 ng/ml low lifetime risk of metastasis and death from prostate cancer may harbor prostate cancer disease is unlikely to become life-threatening?screened on a biennial or triennial basis. 5

Staging/Surveillance Before radical prostatectomy Predict outcomes tumor volume grade of disease biochemical progression Surveillance marker for recurrent disease PSA doubling time post prostatectomy Hormone therapy CRPCa Monitoring 6

PSA density PSA / volume Larger prostates = higher PSA Most helpful 4.0-10 range Subsequent data shows flaws Volume measurements Stromal composition Biopsy sensitivity in large prostates Active surveillance role 7

PSA Velocity Serial PSA measurements greater than 0.75 ng/ml/year increase both the positive predictive value of PSA testing and the likelihood of diagnosing cancers while they are organ-confined Not totally reliable when differentiating between benign and malignant disease Free/Total 25% of biopsies are positive with PSA 2-10 F/T ratio 0-10% 55% to 56% bx + F/T > 25% 8% bx + Larger prostate less likely helpful Can be helpful very high or very low in men smaller glands negative biopsies high total PSA levels. 8

NEW MARKERS! PRO PSA Assd with higher Gleason score Active surveillance role Mens Health Index F/T PSA, propsa Sensitivity 90% Specificity 31.6% Human kallikrein-related peptidase 2 PSA family 4Kscore 80% sensitive, specificity unclear mrna protein PCA3 95% of prostate cancer tissues 6x increase First-void urine (20 to 30 ml) is collected immediately after a digital rectal exam RT-PCR Not influenced by prostate volume Negative <35 = Low risk 9

PCA3 Sensitivity 77% Specificity 57% If previously biopsied and negative PCA3 ~4.5x less likely to have a positive rebiopsy Outperforms PSA on predicting prostate cancer prior to first biopsy MRI New technology in Victoria Used if suspicion of PCa and previous negative biopsy Improves biopsy sensitivity Future unknown 10

Gene Fusion TMPRSS2-ERG gene fusion (T2E) 50% of all cases Urine test possible Sensitivity 45% Specificity 86% Suspect has prognositic value The whole enchilada!!! T2E + PCA3 PSA + PCA3 = Mi-Prostate (MiPS) score 10% = risk of positive biopsy Sens = 80%, Specificity = 90% 11

Summary PSA screening still of value New tests coming, some here Unification of strategies needed PSA values need to be interpreted Overdiagnosis vs overtreatment Canadian Guidelines Offered to all men over 50, annually Over 40 if risk factors (African descent, family history) Baseline in 40 s may be of benefit Must have 10 year life expectancy AUA guidelines suggest that q2y likely OK if previously screen, some studies say q4y Cutoff at age 70 unless very healthy 12